# Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

> **NCT07683806** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 309 (estimated)

## Conditions studied

- Seborrheic Dermatitis

## Interventions

- **DRUG:** Roflumilast Foam 0.3%
- **DRUG:** Vehicle foam

## Key facts

- **NCT ID:** NCT07683806
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-24
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-08-03
- **Target enrollment:** 309 (ESTIMATED)
- **Last updated:** 2026-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683806, "Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*